Benralizumab

FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa)

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear.

Drug facts

Used for: add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. Limitations of Use: Not
for relief of acute bronchospasm or status asthmaticus. Asthma FASENRA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. Limitations of Use: FASENRA is not indicated
for the relief of acute bronchospasm or status asthmaticus. Eosinophilic Granulomatosis with Polyangiitis FASENRA is indicated

What it is used for

FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. Asthma FASENRA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype.

Limitations of Use: FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus. Eosinophilic Granulomatosis with Polyangiitis FASENRA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic Syndrome FASENRA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Benralizumab; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/benralizumab
APA 7th: sofidex. (2026, August 2). Benralizumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/benralizumab
AMA 11th: Benralizumab. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/benralizumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.